Table 1 Patient data
| Â | Number of patients | Sex | Age (years) | (Primary) diagnosis | Extraction location | Additional information | Smoking status |
|---|---|---|---|---|---|---|---|
MRONJ (BP) | 30 | 53.3% women (16) | Ø 67.8 ± 8.89 | 33.33% prostate cancer (10), 30% breast cancer (9), 20% multiple myeloma (6),10% osteoporosis (3), 0.33% renal cell carcinoma (1), 0.33% vertebral sclerosis (1) | 76.7% lower jaw (23), 23.3% upper jaw (7) | 100% nitrogenous. BPs (30): 70% zoledronate (21), 13.3% alendronate (4), 6.6% risedronate (2), 6.6% ibandronate (2), 3.3% pamidronate (1) | 13 smoker, 13 non-smoker, 4 unknown |
OM | 15 | 53.3% women (8) | Ø 43.6 ± 25.20 | 86.6% chronic osteomyelitis (13), 13.3% acute osteomyelitis (2) | 100% lower jaw (15) |  | 6 smoker, 6 non-smoker, 3 unknown |
ORN | 15 | 13.3% women (2) | Ø 57 ± 7.89 | 60% SCC oral cavity (9), 13.3% SCC oropharynx (2), 6.6% SCC hypopharynx (1), 6.6% SCC tonsil (1), 6.6% SCC cranial skin (1), 6.6% CUP | 100% lower jaw (15) | Ø total reference dose in the mandibular region: 68 Gy. (The applicated dose was set individually by the radiotherapists) | 11 smoker, 2 non-smoker, 2 unknown |
CONTROL | 10 | 40% women (4) | Ø 33.8 ± 16.17 | 50% facial fracture (5), 20% dysgnathia (2), 10% cleft lip and palate (1), 10% wisdom tooth extraction (1), 10% arch ratio anomaly (1) | 80% lower jaw (8), 20% upper jaw (2) |  | 2 smoker, 3 non-smoker, 5 unknown |